{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:57:41Z","timestamp":1768219061211,"version":"3.49.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), is characterized by podocyte injury that contributes to disease progression. Dipeptidyl peptidase-4 (DPP-4) inhibitors, though developed for diabetes, have shown renoprotective potential. However, DPP-4 inhibition may elevate CXCL12\/CXCR4 signaling, a pathway implicated in LN pathogenesis. This study aimed to determine whether dual DPP-4 and CXCL12\/CXCR4 blockade confers enhanced renal protection in LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      MRL\/lpr lupus-prone mice were treated with the DPP-4 inhibitor linagliptin, either alone or in combination with the CXCL12\/CXCR4 axis antagonist AMD3100. We evaluated renal function, histopathology, podocyte structure, and markers of oxidative stress, fibrosis, and inflammation.\n                      <jats:italic>In vitro<\/jats:italic>\n                      assays using DPP4-knockout podocytes were also performed to elucidate underlying mechanisms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      DPP4-deficient podocytes exhibited elevated CXCL12\/CXCR4 expression and modest nephrin upregulation. Co-treatment with AMD3100 further increased nephrin expression compared to linagliptin alone.\n                      <jats:italic>In vivo<\/jats:italic>\n                      , linagliptin monotherapy reduced proteinuria and serum creatinine but also increased CXCL12\/CXCR4 expression. Combined therapy significantly decreased proteinuria, serum creatinine, anti-dsDNA, and ANA titers. Histological analysis showed reduced mesangial proliferation and interstitial inflammation. Transmission electron microscopy and immunostaining demonstrated improved podocyte foot process integrity and upregulation of nephrin and podocin. Dual blockade also reduced renal oxidative stress (DHE, NOX4), fibrosis markers (\u03b1-SMA, fibronectin), and inflammatory mediators (NF-\u03baB p65, NLRP3).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combined DPP-4 and CXCL12\/CXCR4 axis inhibition synergistically enhanced podocyte protection and attenuated renal inflammation, fibrosis, and oxidative stress in lupus nephritis. These findings support dual blockade as a promising therapeutic strategy for LN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1732243","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:43:44Z","timestamp":1768196624000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual blockade of DPP-4 and CXCL12\/CXCR4 axes synergistically protects podocytes in lupus nephritis"],"prefix":"10.3389","volume":"16","author":[{"given":"Hui-miao","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-chun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng-yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-jing","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-hui","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-ying","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-de","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan-zheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-yuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Primer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.4049\/jimmunol.170.6.3392","article-title":"Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus","volume":"170","author":"Balabanian","year":"2003","journal-title":"J. Immunol. Balt. Md 1950"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/eji.201747023","article-title":"CXCR4-CXCL12 interaction is important for plasma cell homing and survival in NZB\/W mice","volume":"48","author":"Cheng","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1517\/14728220903196761","article-title":"Targeting the CXCR4\/CXCL12 axis in systemic lupus erythematosus","volume":"13","author":"Chong","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"B5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41581-019-0237-1","article-title":"The power of one: advances in single-cell genomics in the kidney","volume":"16","author":"Clark","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet lond. Engl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1053\/j.ajkd.2015.03.024","article-title":"Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes","volume":"66","author":"Cooper","year":"2015","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"B8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1016\/j.bmc.2013.06.045","article-title":"Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor","volume":"21","author":"Dow","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat. Rev. Dis. Primer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.3390\/cancers15184529","article-title":"Inhibition of dipeptidyl Peptidase-4 activates autophagy to promote survival of breast cancer cells via the mTOR\/HIF-1\u03b1 pathway","volume":"15","author":"Kawakita","year":"2023","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1016\/j.vaccine.2013.05.095","article-title":"Control of humoral immunity and auto-immunity by the CXCR4\/CXCL12 axis in lupus patients following influenza vaccine","volume":"31","author":"Launay","year":"2013","journal-title":"Vaccine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3390\/ijms21030805","article-title":"Deficiency in dipeptidyl Peptidase-4 promotes chemoresistance through the CXCL12\/CXCR4\/mTOR\/TGF\u03b2 signaling pathway in breast cancer cells","volume":"21","author":"Li","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41419-024-06708-4","article-title":"Macrophages communicate with mesangial cells through the CXCL12\/DPP4 axis in lupus nephritis pathogenesis","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1124\/jpet.111.186866","article-title":"Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats","volume":"340","author":"Liu","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1111\/jcmm.14973","article-title":"C-X-C motif chemokine receptor 4 aggravates renal fibrosis through activating JAK\/STAT\/GSK3\u03b2\/\u03b2-catenin pathway","volume":"24","author":"Liu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41419-022-05179-9","article-title":"CD36 aggravates podocyte injury by activating NLRP3 inflammasome and inhibiting autophagy in lupus nephritis","volume":"13","author":"Lv","year":"2022","journal-title":"Cell Death Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/ars.2016.6758","article-title":"C-X-C chemokine receptor type 4 plays a crucial role in mediating oxidative stress-induced podocyte injury","volume":"27","author":"Mo","year":"2017","journal-title":"Antioxid. Redox Signal."},{"key":"B20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.7150\/thno.65948","article-title":"CXCR4 induces podocyte injury and proteinuria by activating \u03b2-catenin signaling","volume":"12","author":"Mo","year":"2022","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/0961203309346906","article-title":"Oxidative stress and homocysteine metabolism in patients with lupus nephritis","volume":"19","author":"Moroni","year":"2010","journal-title":"Lupus"},{"key":"B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2018-213028","article-title":"Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-\u03b1 in lupus nephritis","volume":"77","author":"Qi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.trsl.2023.09.005","article-title":"The CXCR4-AT1 axis plays a vital role in glomerular injury via mediating the crosstalk between podocyte and mesangial cell","volume":"264","author":"Qinyu","year":"2024","journal-title":"Transl. Res. J. Lab. Clin. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1684\/ecn.2007.0103","article-title":"Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus","volume":"18","author":"Robak","year":"2007","journal-title":"Eur. Cytokine Netw."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.kint.2018.08.013","article-title":"CXCL12 blockade preferentially regenerates lost podocytes in cortical nephrons by targeting an intrinsic podocyte-progenitor feedback mechanism","volume":"94","author":"Romoli","year":"2018","journal-title":"Kidney Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41423-023-00974-6","article-title":"The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention","volume":"20","author":"Seppe","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.kint.2016.06.012","article-title":"Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy","volume":"90","author":"Takashima","year":"2016","journal-title":"Kidney Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1021\/acs.biomac.2c00079","article-title":"Study of renal accumulation of targeted polycations in acute kidney injury","volume":"23","author":"Tang","year":"2022","journal-title":"Biomacromolecules"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.kint.2016.01.016","article-title":"The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5\/6 nephrectomy","volume":"89","author":"Tsuprykov","year":"2016","journal-title":"Kidney Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.4049\/jimmunol.0801920","article-title":"CXCR4\/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus","volume":"182","author":"Wang","year":"2009","journal-title":"J. Immunol. Balt. Md 1950"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1002\/art.27685","article-title":"Dysregulated expression of CXCR4\/CXCL12 in subsets of patients with systemic lupus erythematosus","volume":"62","author":"Wang","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s13361-013-0822-7","article-title":"Quantification of intact and truncated stromal cell-derived factor-1\u03b1 in circulation by immunoaffinity enrichment and tandem mass spectrometry","volume":"25","author":"Wang","year":"2014","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"B34","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrneph.2017.85","article-title":"Redefining lupus nephritis: clinical implications of pathophysiologic subtypes","volume":"13","author":"Yu","year":"2017","journal-title":"Nat. Rev. Nephrol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1732243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:43:45Z","timestamp":1768196625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1732243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":35,"alternative-id":["10.3389\/fphar.2025.1732243"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1732243","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1732243"}}